Bilateral striatal transplantation of human olfactory stem cells ameliorates motor function, prevents necroptosis-induced cell death and improves striatal volume in the rat model of Huntington’s disease

Bayat, Amir‐Hossein; Saeidikhoo, Sara; Ebrahimi, Vahid; Mesgar, Somaye; Joneidi, Mohammadjavad; Soltani, Reza; Aghajanpour, Fakhroddin; Mohammadzadeh, Ibrahim; Torabi, Abolfazl; Abdollahifar, Mohammad‐Amin; Bagher, Zohreh; Alizadeh, Rafieh; Aliaghaei, Abbas

doi:10.1016/j.jchemneu.2020.101903

Cited by 21 publications

(23 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found out striatal transplants of OE-MSCs reduced microglial in lammatory factor, TNFα in the 3-NP + Cell group, with a signi icant reduction in RIP3, the markers of necroptosis in striatum. There was a remarkable recovery of intrastriatal volume post grafting and the motor activities were enhanced in the 3-NP + cell group compared to the 3-NP + vehicle group [106].…”

Section: Stem Cell Therapymentioning

confidence: 87%

Multimodal treatment strategies in Huntington’s disease

Dutta¹

2021

Neurosci Neurol Disord

View full text Add to dashboard Cite

Huntington’s disease (HD) is an incurable neurodegenerative disease that causes involuntary movements, emotional lability, and cognitive dysfunction. HD symptoms usually develop between ages 30 and 50, but can appear as early as 2 or as late as 80 years. Currently no neuroprotective and neurorestorative interventions are available. Early multimodal intervention in HD is only possible if the genetic diagnosis is made early. Early intervention in HD is only possible if genetic diagnosis is made at the disease onset or when mild symptoms manifest. Growing evidence and understanding of HD pathomechanism has led researchers to new therapeutic targets. Here, in this article we will talk about the multimodal treatment strategies and recent advances made in this field which can be used to target the HD pathogenesis at its most proximal level.

show abstract

Section: Stem Cell Therapymentioning

confidence: 87%

Multimodal treatment strategies in Huntington’s disease

Dutta¹

2021

Neurosci Neurol Disord

View full text Add to dashboard Cite

show abstract

“…Importantly, secretion of stem cell factor (SCF) by damaged striatum was found to heighten engraftment of MSCs within the damaged brain [ 124 ]. In 2021, Bayat and coworkers showed that intrastriatal transplantation of olfactory ecto-mesenchymal stromal cells (OE-MSC) caused a substantial attenuation in microglial activation and TNFα expression, and also reduced necroptosis in the striatum in the neurotoxin 3-nitropropionic acid (3NP)-induced rat model of HD [ 125 ]. Similarly, in quinolinic acid (QA)-induced rat model of HD, BM-MSC administration ameliorated motor dysfunction and simultaneously sustained striatal volume [ 126 ].…”

Section: Preclinical Studies Based On Msc Therapy In Neurodegenerativ...mentioning

confidence: 99%

Therapeutic utility of mesenchymal stromal cell (MSC)-based approaches in chronic neurodegeneration: a glimpse into underlying mechanisms, current status, and prospects

et al. 2022

View full text Add to dashboard Cite

Recently, mesenchymal stromal cell (MSC)-based therapy has become an appreciated therapeutic approach in the context of neurodegenerative disease therapy. Accordingly, a myriad of studies in animal models and also some clinical trials have evinced the safety, feasibility, and efficacy of MSC transplantation in neurodegenerative conditions, most importantly in Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington’s disease (HD). The MSC-mediated desired effect is mainly a result of secretion of immunomodulatory factors in association with release of various neurotrophic factors (NTFs), such as glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF). Thanks to the secretion of protein-degrading molecules, MSC therapy mainly brings about the degradation of pathogenic protein aggregates, which is a typical appearance of chronic neurodegenerative disease. Such molecules, in turn, diminish neuroinflammation and simultaneously enable neuroprotection, thereby alleviating disease pathological symptoms and leading to cognitive and functional recovery. Also, MSC differentiation into neural-like cells in vivo has partially been evidenced. Herein, we focus on the therapeutic merits of MSCs and also their derivative exosome as an innovative cell-free approach in AD, HD, PD, and ALS conditions. Also, we give a brief glimpse into novel approaches to potentiate MSC-induced therapeutic merits in such disorders, most importantly, administration of preconditioned MSCs.

show abstract

“…77 Bilateral striatal transplantation of human olfactory stem cells has been reported to potentially reduce the levels of microglial inflammatory factor, TNF, and significantly reduces RIPK3, thereby highlighting that the mechanism of stem cell therapy involved necroptotic pathway regulation. 77 2.1.5. Multiple Sclerosis.…”

Section: Degeneration Diseases 211 Alzheimer's Diseasementioning

confidence: 99%

Role of Necroptosis in Central Nervous System Diseases

Shao

Wang

et al. 2022

ACS Chem. Neurosci.

View full text Add to dashboard Cite

Necroptosis is a type of precisely regulated necrotic cell death activated in caspase-deficient conditions. Multiple factors initiate the necroptotic signaling pathway, including toll-like receptor 3/4, tumor necrosis factor (TNF), dsRNA viruses, and T cell receptors. Presently, TNF-induced necroptosis via the phosphorylation of three key proteins, receptor-interacting protein kinase 1, receptor-interacting protein kinase 3, and mixed lineage kinase domain-like protein, is the best-characterized process. Necroptosis induced by Z-DNA-binding protein 1 (ZBP-1) and toll/interleukin-1 receptor (TIR)-domain-containing adapter-inducing interferon (TRIF) plays a significant role in infectious diseases, such as influenza A virus, Zika virus, and herpesvirus infection. An increasing number of studies have demonstrated the close association of necroptosis with multiple diseases, and disrupting necroptosis has been confirmed to be effective for treating (or managing) these diseases. The central nervous system (CNS) exhibits unique physiological structures and immune characteristics. Necroptosis may occur without the sequential activation of signal proteins, and the necroptosis of supporting cells has more important implications in disease development. Additionally, necroptotic signals can be activated in the absence of necroptosis. Here, we summarize the role of necroptosis and its signal proteins in CNS diseases and characterize typical necroptosis regulators to provide a basis for the further development of therapeutic strategies for treating such diseases. In the present review, relevant information has been consolidated from recent studies (from 2010 until the present), excluding the patents in this field.

show abstract

Bilateral striatal transplantation of human olfactory stem cells ameliorates motor function, prevents necroptosis-induced cell death and improves striatal volume in the rat model of Huntington’s disease

Cited by 21 publications

References 65 publications

Multimodal treatment strategies in Huntington’s disease

Multimodal treatment strategies in Huntington’s disease

Therapeutic utility of mesenchymal stromal cell (MSC)-based approaches in chronic neurodegeneration: a glimpse into underlying mechanisms, current status, and prospects

Role of Necroptosis in Central Nervous System Diseases

Contact Info

Product

Resources

About